Thrombosis-related complications and mortality in cancer patients with central venous devices: an observational study on the effect of antithrombotic prophylaxis

Geerts, 2004, Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy, Chest, 126, 338S, 10.1378/chest.126.3_suppl.338S Verso, 2005, Enoxaparin for the prevention of venous thromboembolism associated with central vein catheter: a double-blind, placebo- controlled, randomized study in cancer patients, J Clin Oncol, 23, 4057, 10.1200/JCO.2005.06.084 Karthaus, 2006, Dalteparin for prevention of catheter-related complications in cancer patients with central venous catheters: final results of a double-blind, placebo-controlled phase III trial, Ann Oncol, 17, 289, 10.1093/annonc/mdj059 Couban, 2005, Randomized placebo-controlled study of low-dose warfarin for the prevention of central venous catheter-associated thrombosis in patients with cancer, J Clin Oncol, 23, 4063, 10.1200/JCO.2005.10.192 Monreal, 1996, Upper extremity deep venous thrombosis in cancer patients with venous access devices—prophylaxis with a low molecular weight heparin (Fragmin), Thromb Haemost, 75, 251, 10.1055/s-0038-1650254 Bern, 1990, Very low doses of warfarin can prevent thrombosis in central venous catheters. A randomized prospective trial, Ann Intern Med, 112, 423, 10.7326/0003-4819-76-3-112-6-423 Verso, 2003, Venous thromboembolism associated with long-term use of central venous catheters in cancer patients, J Clin Oncol, 21, 3665, 10.1200/JCO.2003.08.008 Levine, 1994, Double-blind randomised trial of a very low dose warfarin for prevention of thromboembolism in stage IV breast cancer, Lancet, 343, 886, 10.1016/S0140-6736(94)90008-6 Geerts, 2001, Prevention of venous thromboembolism, Chest, 119, 132S, 10.1378/chest.119.1_suppl.132S Carr, 2000, Physician compliance with warfarin prophylaxis for central venous catheters in patients with solid tumors, J Clin Oncol, 18, 3665, 10.1200/JCO.2000.18.21.3665 Lee, 2006, Incidence, risk factors, and outcomes of catheter-related thrombosis in adult patients with cancer, J Clin Oncol, 24, 1404, 10.1200/JCO.2005.03.5600 De Cicco, 1997, Central venous thrombosis: an early and frequent complication in cancer patients bearing long-term silastic catheter. A prospective study, Thromb Res, 86, 101, 10.1016/S0049-3848(97)00054-6 Cortelezzi, 2005, CATHEM Study Group. Incidence of thrombotic complications in patients with haematological malignancies with central venous catheters: a prospective multicentre study, Br J Haematol, 129, 811, 10.1111/j.1365-2141.2005.05529.x Taliani, 2003, Warfarin Optimal Duration Italian Trial (WODIT) Investigators. Incidence of cancer after a first episode ofidiopathic venous thromboembolism treated with 3 months or 1 year of oral anticoagulation, J Thromb Haemost, 1, 1730, 10.1046/j.1538-7836.2003.00293.x Schulman, 2000, Incidence of cancer after prophylaxis with warfarin against recurrent venous thromboembolism. Duration of Anticoagulation Trial, N Engl J Med, 342, 1953, 10.1056/NEJM200006293422604 Huisman, 2006, Is antithrombotic prophylaxis required in cancer patients with central venous catheters? Yes for special patient groups, J Thromb Haemost, 4, 10, 10.1111/j.1538-7836.2005.01735.x